Literature DB >> 2539172

Germ cell tumour chemotherapy.

A Horwich1.   

Abstract

Mesh：

Year:  1989        PMID： 2539172      PMCID： PMC2246990          DOI： 10.1038/bjc.1989.33

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  32 in total

1.  The management of advanced testicular teratoma.

Authors:  M J Peckham; A Horwich; D F Easton; W F Hendry
Journal:  Br J Urol       Date:  1988-07

2.  Cytoreductive surgery for metastatic testis cancer: tissue analysis of retroperitoneal masses after chemotherapy.

Authors:  J P Donohue; L M Roth; J M Zachary; R G Rowland; L H Einhorn; S G Williams
Journal:  J Urol       Date:  1982-06       Impact factor: 7.450

3.  Multivariate analysis of prognostic variables in patients with metastatic testicular cancer.

Authors:  G J Bosl; N L Geller; C Cirrincione; N J Vogelzang; B J Kennedy; W F Whitmore; D Vugrin; H Scher; J Nisselbaum; R B Golbey
Journal:  Cancer Res       Date:  1983-07       Impact factor: 12.701

4.  Chemotherapy of disseminated testicular cancer. A random prospective study.

Authors:  L H Einhorn; S D Williams
Journal:  Cancer       Date:  1980-09-15       Impact factor: 6.860

5.  A randomized trial of standard chemotherapy v a high-dose chemotherapy regimen in the treatment of poor prognosis nonseminomatous germ-cell tumors.

Authors:  R F Ozols; D C Ihde; W M Linehan; J Jacob; Y Ostchega; R C Young
Journal:  J Clin Oncol       Date:  1988-06       Impact factor: 44.544

6.  Cisplatin-based combination chemotherapy for disseminated germ cell tumors: long-term follow-up.

Authors:  B J Roth; A Greist; P S Kubilis; S D Williams; L H Einhorn
Journal:  J Clin Oncol       Date:  1988-08       Impact factor: 44.544

7.  A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumors.

Authors:  G J Bosl; N L Geller; D Bajorin; S P Leitner; A Yagoda; R B Golbey; H Scher; N J Vogelzang; J Auman; R Carey
Journal:  J Clin Oncol       Date:  1988-08       Impact factor: 44.544

8.  Comparison of criteria for assigning germ cell tumor patients to "good risk" and "poor risk" studies.

Authors:  D Bajorin; A Katz; E Chan; N Geller; N Vogelzang; G J Bosl
Journal:  J Clin Oncol       Date:  1988-05       Impact factor: 44.544

9.  Chemotherapy with maximally tolerable doses of VP 16-213 and cyclophosphamide followed by autologous bone marrow transplantation for the treatment of relapsed or refractory germ cell tumors.

Authors:  P O Mulder; E G de Vries; H S Koops; T Splinter; A Maas; S van der Geest; N H Mulder; D T Sleijfer
Journal:  Eur J Cancer Clin Oncol       Date:  1988-04

10.  The treatment of metastatic germ-cell testicular tumours with bleomycin, etoposide and cis-platin (BEP).

Authors:  M J Peckham; A Barrett; K H Liew; A Horwich; B Robinson; H J Dobbs; T J McElwain; W F Hendry
Journal:  Br J Cancer       Date:  1983-05       Impact factor: 7.640
View more
  2 in total

1.  Advances in the management of metastatic non-seminomatous germ cell tumours during the cisplatin era: a single-institution experience.

Authors:  A Gerl; C Clemm; N Schmeller; R Hartenstein; R Lamerz; W Wilmanns
Journal:  Br J Cancer       Date:  1996-10       Impact factor: 7.640

Review 2.  A Scottish national audit of current patterns of management for patients with testicular non-seminomatous germ-cell tumours. The Scottish Radiological Society and the Scottish Committee of the Royal College of Radiologists.

Authors:  G C Howard; K Clarke; M H Elia; A W Hutcheon; S B Kaye; P M Windsor
Journal:  Br J Cancer       Date:  1995-11       Impact factor: 7.640
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.